Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1603-1605

  Liu, Changle ^a   Liu, Tong ^a   Li, Guangping ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Diabetes mellitus; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; C REACTIVE PROTEIN; CALCIUM CHANNEL L TYPE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STREPTOZOCIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CALCIUM CURRENT; CARDIOVASCULAR PARAMETERS; CHRONIC DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART ATRIAL REMODELING; HEART ATRIUM; HEART ATRIUM CONDUCTION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE HYPERTROPHY; HYPERGLYCEMIA; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LETTER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINUS NODE CONDUCTION VELOCITY; SMOOTH MUSCLE FIBER; SODIUM CURRENT;

ATRIAL FIBRILLATION; DIABETES MELLITUS; PIOGLITAZONE;

ATRIAL FIBRILLATION; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 84885308610     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.037     Document Type: Article

References (44)

1. Liu T, Li G. Antioxidant Interventions as novel preventive strategies for postoperative atrial fibrillation. Int J Cardiol 2010;145:140-2.
2. Liu T, Li G. Inflammation: another potential mechanism between diabetes mellitus and atrial fibrillation. Am J Cardiol 2008;101:1681-2.
3. Movahed MR, Hashemzadeh M, Jamal MM. diabetes mellitus Is a strong, Independent risk for atrial fibrillation and flutter In addition to other cardiovascular disease. Int J Cardiol 2005;105:315-21.
4. Lip GY, Varughese Gi. diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathoPhysiological links. Int J Cardiol 2005;105:319-21.
5. Kume O, Takahashi N,Wakisaka O, et al. Pioglitazone attenuates Inflammatory atrial fibrosis and vulnerability to atrial fibrillation Induced by pressure overload In rats. Heart Rhythm 2011;8:278-85.
6. Liu T, Li G. Thiazolidinediones as novel upstream therapy for atrial fibrillation In diabetic patients: a review of current evidence. Int J Cardiol 2012;156:215-6.
7. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108:56-62.
8. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008;117:1255-60.
9. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to Increased prevalence and Incidence of atrial fibrillation. diabetes Care 2009;32:1851-6.
10. Dublin S, Glazer NL, Smith NL, et al. diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853-8.
11. Kato T, Yamashita T, Sekiguchi A, et al. Ages-rage system mediates atrial structural remodeling In the diabetic rat. J Cardiovasc ElectroPhysiol 2008;19:415-20.
12. Karaca M, Kinay O, Nazli C, et al. The time Interval from the Initiation of the Pwave to the start of left atrial appendage ejection flow: does It reflect Interatrial conduction time? Echocardiography 2007;24:810-5.
13. Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates In diabetic rat atria? J Cardiovasc ElectroPhysiol 2006;17:890-4.
14. Pacher P, Ungvari Z, Nanasi PP, Kecskemeti V. ElectroPhysiological changes In rat ventricular and atrial myocardium at different stages of experimental diabetes. Acta Physiol Scand 1999;166:7-13.
15. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying Ionic remodeling In a dog model of atrial fibrillation. Circ Res 1999;84:776-84.
16. Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial Interstitial fibrosis, Ionic remodeling and vulnerability to atrial fibrillation In diabetic rabbits. Anadolu Kardiyol Derg 2012;12:543-50.
17. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70.
18. Liu T, Li G, Korantzopoulos P, Goudevenos JA. Statins and prevention of atrial fibrillation In patients with heart failure. Int J Cardiol 2009;135:e83-4.
19. Liu E, Xu Z, Li J, et al. Enalapril, Irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced Ionic remodeling. Int J Cardiol 2011;146:364-70.
20. Liu T, Korantzopoulos P, Shehata M, et al. Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart 2011;97:1034-40.
21. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated Inflammation. Int J Cardiol 2005;102:321-6.
22. Rasoli S, Kakouros N, Harling L, et al. Antioxidant vitamins In the prevention of atrial fibrillation: what Is the evidence? Cardiol Res Pract 2011;164078.
23. Liu T, Li G. Probucol and succinobucol In atrial fibrillation: pros and cons. Int J Cardiol 2010;144:295-6.
24. Liu T, Li G. Antioxidant Interventions as novel preventive strategies for postoperative atrial fibrillation. Int J Cardiol 2010;145:140-2.
25. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones In atrial fibrillation. Int J Cardiol 2008;128:129-30.
26. Villegas I, Martin AR, Toma W, de la Lastra CA. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric Ischemia-Reperfusion damage In rats: role of oxygen free radicals generation. Eur J Pharmacol 2004;505:195-203.
27. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006;97:655-8.
28. Gilde AJ, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. J Am Coll Cardiol 2006;48:A24-32.
29. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004;27:982-91.
30. Ghanim H, Garg R, Aljada A. Suppression of nuclear factor-κB and stimulation of Inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect In the obese. J Clin Endocrinol Metab 2001;86:1306-12.
31. Iglarz M, Touyz RM, Viel EC, et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis In mineralocorticoid-dependent Hypertension. Hypertension 2003;42:737-43.
32. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferatoractivated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial Infarction. Circulation 2002;106:3126-32.
33. Nakajima T, Iwasawa K, Oonuma H, et al. Troglitazone Inhibits voltagedependent calcium currents In guinea pig cardiac myocytes. Circulation 1999;99:2942-50.
34. Gumieniczek A. Effects of pioglitazone on hyperglycemia Induced alterations In antioxidative system In tissues of alloxan-treated diabetic animals. Exp Toxicol Pathol 2005;56:321-6.
35. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates Inflammatory atrial fibrosis and vulnerability to atrial fibrillation Induced by pressure overload In rats. Heart Rhythm 2011;8:278-85.
36. Xu D,Murakoshi N, IgarashiM, et al. PPAR-γ activator pioglitazone prevents agerelated atrial fibrillation susceptibility by Improving antioxidant capacity and reducing apoptosis In a rat model. J Cardiovasc ElectroPhysiol 2012;23:209-17.
37. Toblli JE, Cao G, Giani JF, et al. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the Improvement of IL-6 TNF-aα-markers of cell turnover, tubular and endothelial Integrity, and angiogenesis. Kidney Blood Press Res 2011;34:20-33.
38. Gumieniczek A, Hopkala H, Rolinski J, Bojarska-Junak A. Interleukin-6 and oxidative stress In plasma of alloxan-induced diabetic rabbits after pioglitazone treatment. Immunopharmacol Immunotoxicol 2006;28:81-91.
39. Bagi Z, Koffer A, Kaley G. PPARgamma activation by reducing oxidative stress Increases NO bioavailability In coronary artericles of micewith type 2 diabetes. Am J Physiol Heart Circ Physiol 2004;286:H742-8.
40. Li D, fareh S, Leang TK, Nattel S. Promotion of atrial fibrillation by heart failure In dogs: atrial remodeling of a different sort. Circulation 1999;100:87-92.
41. Kaminski KA, Szepietowska B, Bonda T, et al. CCN2 protein Is an announcing marker for cardiac remodeling following STZ-induced moderate hyperglycemia In mice. Pharmacol Rep 2009;61:496-503.
42. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signalregulated kinase and angiotensin-converting enzyme In human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
43. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling In atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204.
44. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferators-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion In rabbits with congestive heart failure. Heart Rhythm 2008;5:451-9.